Hospital
Prime Healthcare Services - San Dimas LLC
Prime Healthcare Services - San Dimas LLC was paid $2.92M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 0450, Emergency room services — 34% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - SAN DIMAS LLC
SAN DIMAS, CA 91773
SAN DIMAS, CA 91773
33aNPI1740447945assigned 05/16/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.92M
24GClaims162,472
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#246 of 410
Median peer was paid$6.90M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,678 | $420K | |
| 2019 | 24,026 | $430K | |
| 2020 | 17,579 | $318K | |
| 2021 | 20,727 | $377K | |
| 2022 | 24,347 | $466K | |
| 2023 | 25,774 | $491K | |
| 2024incomplete | 23,341 | $413K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 34% | 26,446 | 24,063 | $980K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.6% | 1,983 | 1,935 | $191K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.0% | 2,073 | 2,015 | $175K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 3,746 | 3,541 | $151K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.7% | 2,988 | 2,683 | $107K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 5,020 | 4,727 | $91K |
| 99199 | Unlisted special service, procedure or report | 3.0% | 2,604 | 2,375 | $88K |
| 80053 | Comprehensive metabolic panel | 2.5% | 9,010 | 8,422 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 4,759 | 4,524 | $72K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 3,081 | 2,933 | $71K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 1,330 | 1,263 | $66K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 5,729 | 5,493 | $65K |
108 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 11,226 | $58K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 3,056 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 1,481 | $52K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 952 | $48K |
| 99284 | Emergency room visit (serious) | 1.4% | 441 | $41K |
| 99285 | Emergency room visit (most serious) | 1.4% | 271 | $40K |
| Z7502 | 1.2% | 898 | $34K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 2,538 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 480 | $24K |
| 84484 | <1% | 3,528 | $24K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 263 | $22K |
| 83880 | <1% | 1,125 | $20K | |
| 83690 | <1% | 3,923 | $18K | |
| J3490 | Unclassified drugs | <1% | 4,351 | $18K |
| 81025 | <1% | 4,357 | $17K | |
| 83605 | <1% | 2,358 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,535 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,354 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,573 | $12K |
| 0250 | <1% | 3,476 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 954 | $12K |
| 0270 | <1% | 2,734 | $12K | |
| 87040 | <1% | 1,410 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,930 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,767 | $11K |
| 99070 | <1% | 381 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,019 | $10K |
| 86710 | <1% | 947 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 202 | $8K |
| 85730 | <1% | 2,020 | $8K | |
| 81000 | <1% | 3,470 | $8K | |
| 85610 | <1% | 2,587 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,203 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 838 | $5K |
| 70140 | <1% | 31 | $5K | |
| 80076 | <1% | 928 | $5K | |
| 82150 | <1% | 964 | $4K | |
| 82397 | <1% | 411 | $4K | |
| 0011A | <1% | 101 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 201 | $3K |
| 82550 | <1% | 598 | $3K | |
| 81003 | <1% | 2,112 | $3K | |
| 87081 | <1% | 697 | $3K | |
| 86403 | <1% | 361 | $2K | |
| 81001 | <1% | 1,195 | $2K | |
| 0012A | <1% | 61 | $2K | |
| 86140 | <1% | 625 | $2K | |
| Z9725 | <1% | 74 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $2K |
| 74018 | <1% | 121 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 613 | $2K |
| 84702 | <1% | 255 | $2K | |
| 73030 | <1% | 94 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 742 | $2K |
| 73610 | <1% | 96 | $2K | |
| 90715 | <1% | 53 | $2K | |
| 84703 | <1% | 346 | $2K | |
| 73630 | <1% | 62 | $1K | |
| 81002 | <1% | 573 | $1K | |
| 0360 | <1% | 204 | $1K | |
| 73564 | <1% | 51 | $989.95 | |
| 85379 | <1% | 139 | $904.99 | |
| 87186 | <1% | 165 | $895.38 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 213 | $822.27 |
| 0300 | <1% | 12 | $796.92 | |
| 72100 | <1% | 26 | $768.89 | |
| 99499 | <1% | 15 | $744.00 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 39 | $610.30 |
| 87420 | <1% | 120 | $596.57 | |
| 0320 | <1% | 44 | $550.26 | |
| 82962 | <1% | 287 | $529.35 | |
| 73130 | <1% | 26 | $516.41 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 475 | $499.19 |
| 82009 | <1% | 124 | $375.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 126 | $371.94 |
| 0636 | <1% | 87 | $369.35 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 207 | $361.71 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 99 | $324.86 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 514 | $310.52 |
| 76376 | <1% | 536 | $300.63 | |
| 82948 | <1% | 138 | $296.17 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 38 | $266.11 |
| 86901 | <1% | 78 | $223.13 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 170 | $199.96 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17 | $191.85 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $191.40 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $190.41 |
| 85027 | <1% | 37 | $158.42 | |
| A4649 | Surgical supply; miscellaneous | <1% | 40 | $147.15 |
| 81015 | <1% | 189 | $130.19 | |
| 96376 | <1% | 16 | $105.75 | |
| 86900 | <1% | 27 | $81.25 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $78.13 |
| 85651 | <1% | 25 | $63.44 | |
| 85007 | <1% | 24 | $50.46 | |
| 29125 | <1% | 12 | $50.00 | |
| 80061 | Lipid panel | <1% | 47 | $47.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 13 | $28.78 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $27.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29 | $11.09 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $10.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $10.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 90 | $8.78 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 97 | $3.66 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 14 | $0.83 |
| 88313 | 0% | 12 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 12 | $0.00 |
| 88312 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.